Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $103.00 Price Target at Morgan Stanley

Summary by MarketBeat
Morgan Stanley reduced their target price on shares of BioMarin Pharmaceutical from $119.00 to $103.00 and set an "overweight" rating on the stock in a report on Friday.

1 Articles

MarketBeatMarketBeat
Center

BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $103.00 Price Target at Morgan Stanley

Morgan Stanley reduced their target price on shares of BioMarin Pharmaceutical from $119.00 to $103.00 and set an "overweight" rating on the stock in a report on Friday.

·Sioux Falls, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MarketBeat broke the news in Sioux Falls, United States on Friday, November 13, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Morgan Stanley icon

Morgan Stanley

Stock Markets icon

Stock Markets

San Rafael icon

San Rafael

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal